The Rise of Digital Therapeutics Beyond Prescription Apps

Lucas and Luna explore the emerging world of digital therapeutics — software-based treatments that are FDA-cleared to treat medical conditions. They focus on Akili Interactive's EndeavorRx, the first prescription video game for ADHD, and discuss the business challenges facing the digital therapeutic industry: reimbursement, physician adoption, and patient engagement. Lucas explains how Akili pivoted from a prescription-only model to a direct-to-consumer subscription in 2024, and what that shift means for the category's future. They compare EndeavorRx to other digital therapeutic companies like Pear Therapeutics (which filed for bankruptcy in 2023) to illustrate the market's growing pains. The episode closes with a look at what it will take for digital therapeutics to move from niche to mainstream, including potential partnerships with pharma and payers. #DigitalTherapeutics #EndeavorRx #AkiliInteractive #ADHD #PearTherapeutics #FDA #DTx #PrescriptionDigitalTherapeutics #HealthTech #BusinessStrategy #RegulatoryApproval #Reimbursement #PayerAdoption #PharmaPartnerships #Gamification #MentalHealth #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo